Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Related LGND
18 Biggest Mid-Day Gainers For Wednesday
Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'

In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $23.00 to $26.00.

In the report, Rivkind noted, “On March 14 the company announced its license and global supply agreement with Spectrum Pharmaceuticals on Captisol-enabled Melphalan for the treatment of multiple myeloma. Ligand received a $3M upfront payment and negotiated a healthy double-digit royalty (we estimate 20%) in addition to $50M in milestones that will be based on multiple regulatory and commercial events such as NDA acceptance, FDA approval, and launch. Spectrum is also taking over development costs, effective immediately.”

Ligand Pharmaceuticals closed on Friday at $23.27.

Latest Ratings for LGND

Sep 2016Deutsche BankUpgradesSellHold
Aug 2016Deutsche BankDowngradesHoldSell
Apr 2016Stephens & Co.Initiates Coverage onOverweight

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings


Related Articles (LGND)

View Comments and Join the Discussion!